GlassScriptPhysician profile
Muhammad M Aboudan
NPI 1457308702
$6,360.98
in general payments reported to CMS, 2019-2025
46 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $650 · 2021: $739 · 2022: $994 · 2023: $977 · 2024: $954 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.56 |
| Education | $174.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $841.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $656.27 | 2019-2025 | Airsupra, Fasenra, Symbicort |
| Actelion Pharmaceuticals US, INC. | $410.66 | 2019-2025 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $369.52 | 2020-2024 | Wakix |
| Insmed, INC. | $337.86 | 2019-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $330.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.47 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $252.63 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Jazz Pharmaceuticals INC. | $248.90 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $242.45 | 2019-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $216.67 | 2019-2025 | |
| Intuitive Surgical, INC. | $214.48 | 2021-2022 | |
| Mylan Specialty L.P. | $130.45 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $128.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.50 | 2020-2025 | Glassia |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $124.56 | 2019-2022 | |
| Resmed Corp | $124.15 | 2019-2025 | |
| Inogen, INC. | $106.67 | 2022-2023 | Inogen |
| Baxter Healthcare | $94.20 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $88.42 | 2019-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $88.09 | 2020-2023 | Acthar |
| Inspire Medical Systems, INC. | $87.73 | 2024-2025 | Inspire |
| Gilead Sciences, INC. | $74.16 | 2022-2023 | Veklury |
| Janssen Pharmaceuticals, INC | $73.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $63.78 | 2019-2021 | |
| Philips North America LLC | $61.98 | 2020-2025 | (8874) Incourage, Vest Therapy Und |
| Amgen INC. | $57.11 | 2025 | Tezspire, Tavneos |
| Allergan, INC. | $51.90 | 2019-2020 | |
| Pulmonx Corporation | $49.82 | 2021 | |
| Abbvie INC. | $39.73 | 2023-2025 | Avycaz |
| Viatris Specialty LLC | $34.58 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $34.50 | 2023 | Purified Cortrophin Gel |
| Shire North American Group INC | $31.60 | 2019 | |
| Electromed, INC. | $31.36 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $23.05 | 2025 | Lumryz |
| Liquidia Technologies, INC. | $22.22 | 2025 | Yutrepia |
| Vifor Pharma, INC. | $21.67 | 2025 | Zemaira |
| Sanofi-Aventis U.S. LLC | $19.64 | 2021 | |
| Circassia INC. | $18.70 | 2019 | |
| Lilly USA, LLC | $17.53 | 2025 | Zepbound |
| Mayne Pharma Commercial LLC | $17.40 | 2022 | |
| Smith+Nephew, INC. | $16.48 | 2023 | Grafix Pl |
| Pfizer INC. | $15.89 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.45 | 2019 | |
| Veran Medical Technologies, INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Aboudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.